Signaturefd, LLC Supernus Pharmaceuticals, Inc. Call Options Transaction History
Signaturefd, LLC
- $5.2 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SUPN
# of Institutions
258Shares Held
59.3MCall Options Held
47.9KPut Options Held
13.1K-
Black Rock Inc. New York, NY10.4MShares$355 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.14MShares$210 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.27MShares$180 Million1.83% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.87MShares$97.9 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.68MShares$91.5 Million0.08% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.83B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...